• GenFleet Therapeutics secured Chinese clinical trial approvals for combinations of oral pan-RAS inhibitor GFH276 since the third quarter of 2026.
• Clinical trial notifications were also completed in Australia. Phase Ib/II studies target RAS-mutant cancers in first-line and later-line settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261104-12398432), on November 03, 2026, and is solely responsible for the information contained therein.